Author

H. Gruell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 9 Biophysics· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 9 Organism:human· 9 Assay:proteomics· 6 Research Focus:cell type annotation· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

F. Klein· 12 shared K. Vanshylla· 9 shared C. Kreer· 6 shared M. Zehner· 5 shared P. Schommers· 5 shared L. Gieselmann· 4 shared M. Koch· 4 shared M. Korenkov· 4 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

12 shared papersImmunology

F. Klein

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape

M. Korenkov, M. Zehner, H. Cohen-Dvashi, A. Borenstein-Katz, L. Kottege, H. Janicki, K. Vanshylla, T. Weber, H. Gruell, M. Koch, R. Diskin, C. Kreer, F. Klein

The paper reverts mutations in SARS-CoV-2 antibodies to study SHM's impact on neutralization, finding that some mutations are critical for neutralizing Omicron variants.

bioRxiv · May 9, 2023 · PreprintImmunology

Neutralization sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage

H. Gruell, K. Vanshylla, P. Tober-Lau, D. Hillus, L. E. Sander, F. Kurth, F. Klein

This study evaluates the neutralization sensitivity of the SARS-CoV-2 BA.2.75 sublineage compared to other variants, finding it less resistant to antibodies than BA.4/5 but more than BA.2.

bioRxiv · Aug 4, 2022 · PreprintImmunology

Probabilities of HIV-1 bNAb development in healthy and chronically infected individuals

C. Kreer, C. Lupo, M. S. Ercanoglu, L. Gieselmann, N. Spisak, J. Grossbach, M. Schlotz, P. Schommers, H. Gruell, L. Dold, A. Beyer, A. Nourmohammad, T. Mora, A. Walczak, F. Klein

The paper uses sequence analysis to predict the likelihood of HIV-1 broadly neutralizing antibody (bNAb) development in healthy and infected individuals, finding that chronic infection is not required for bNAb generation.

bioRxiv · Jul 11, 2022Immunology

Delineating antibody escape from Omicron sublineages

H. Gruell, K. Vanshylla, M. Korenkov, P. Tober-Lau, M. Zehner, F. Muenn, H. Janicki, M. Augustin, P. Schommers, L. E. Sander, F. Kurth, C. Kreer, F. Klein

This study evaluates antibody escape from Omicron sublineages by testing serum and monoclonal antibody activity against BA.1, BA.2, BA.2.12.1, and BA.4/5, revealing increased resistance in BA.4/5 and identifying promising neutralizing antibodies.

bioRxiv · Apr 6, 2022 · PreprintImmunology

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation

C. O. Barnes, T. Schoofs, P. N. P. Gnanapragasam, J. Golijanin, K. E. Huey-Tubman, H. Gruell, P. Schommers, N. Suh-Toma, Y. E. Lee, J. C. C. Lorenzi, A. Piechocka-Trocha, J. F. Scheid, A. P. West, B. D. Walker, M. S. Seaman, , P. J. Bjorkman

This paper describes a VRC01-class antibody with lower somatic mutation but comparable breadth and potency to other broadly neutralizing antibodies against HIV-1.

bioRxiv · Mar 16, 2022Immunology

No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults

M. S. Ercanoglu, L. Gieselmann, S. Daehling, N. Poopalasingam, S. Detmer, M. Koch, M. Korenkov, S. Halwe, M. Kluever, V. Di Cristanziano, U. H. Janicki, M. Schlotz, J. Worczinski, B. Gathof, H. Gruell, , F. Klein

The paper analyzes B cell immunity in unexposed adults and finds no substantial pre-existing antibody or B cell response to SARS-CoV-2.

bioRxiv · Sep 8, 2021Immunology

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

S. Halwe, A. Kupke, K. Vanshylla, F. Liberta, H. Gruell, M. Zehner, C. Rohde, V. Kraehling, M. Gellhorn-Serra, C. Kreer, M. Kluever, L. Sauerhering, J. Schmidt, Z. Cai, F. Han, , S. Becker

This paper describes a monoclonal antibody, DZIF-10c, that effectively neutralizes SARS-CoV-2 and its variants when administered intranasally to mice, offering potential for topical treatment.

bioRxiv · Jun 9, 2021Microbiology

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2

K. Vanshylla, V. Di Cristianziano, F. Kleipass, F. Dewald, P. Schommers, L. Gieselmann, H. Gruell, M. Schlotz, M. S. Ercanoglu, R. Stumpf, P. Mayer, E. Heger, W. Johannis, C. Horn, I. Suarez, , F. Klein

This study examines the kinetics and correlates of the SARS-CoV-2 neutralizing antibody response in 963 recovered individuals over 10 months, finding variations in antibody persistence and identifying factors predicting neutralizing activity.

bioRxiv · Jan 26, 2021 · PreprintImmunology

A novel humanized mouse model to study mucosal HIV-1 transmission and prevention

K. Vanshylla, K. Held, T. Eser, H. Gruell, K. Jain, D. Weiland, J. Muench, B. Gruettner, C. Geldmacher, F. Klein

This paper introduces a novel humanized mouse model, CD34T+, which is highly permissive to mucosal HIV-1 infection and can be prevented by broadly neutralizing antibodies.

bioRxiv · Aug 31, 2020Immunology

Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody

M. Meijers, K. Vanshylla, H. Gruell, F. Klein, M. Laessig

The paper models HIV-1 escape dynamics from broadly neutralizing antibodies using clinical trial data, identifying fitness factors that predict viral reproduction rates and resistance tradeoffs.

bioRxiv · Aug 6, 2020Biophysics

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

C. Kreer, M. Zehner, T. Weber, C. Rohde, S. Halwe, M. S. Ercanoglu, L. Gieselmann, M. Korenkov, H. Gruell, P. Schommers, K. Vanshylla, V. Di Cristanziano, H. Janicki, R. Brinker, A. Ashurov, , F. Klein

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.

bioRxiv · Jun 12, 2020Immunology

SARS-CoV-2 targets cortical neurons of 3D human brain organoids and shows neurodegeneration-like effects

J. Gopalakrishnan, A. Ramani, L. Mueller, P. Niklas Ostermann, E. Gabriel, A. Islam Pranty, A. Mueller-Shiffmann, A. Mariappan, O. Goureau, H. Gruell, A. Walker, M. Andree, S. Hauka, K. Wohlgemuth, H. Omran, , A. Dilthey

This study shows SARS-CoV-2 infects cortical neurons in 3D human brain organoids, causing neurodegeneration-like effects such as Tau mislocalization and neuronal death.

bioRxiv · May 20, 2020Cell Biology